drugset / Trial / NCT00911235

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

NCT00911235

Phase 1 Completed 28 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

This study is designed to estimate the effect of fluconazole (200 mg BID for 2 days), a moderate CYP3A4 inhibitor on the pharmacokinetics of a single 8 mg oral dose of fesoterodine in healthy adult subjects.

Timeline

Start
2009-05
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 8 mg Oral
Subject Fluconazole Small molecule 200 mg Oral

Indications